Ironwood Pharmaceuticals Inc (IRWD) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Ironwood Pharmaceuticals Inc $4.23, price $4.27, upside -0.9%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ironwood Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.5663 – $15.45 · fair‑value band $3.18 – $6.18 · the $4.27 price screens above the $4.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Ironwood Pharmaceuticals in your weekly email
Every Wednesday you see whether Ironwood Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Show more
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Stock analysis
Ironwood Pharmaceuticals Inc (IRWD) currently trades at $4.27, while our model-based Fair Value estimate is $4.23, implying the stock looks roughly 0.9% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $8.46 per share, and 13 of the 21 models we run sit above the $4.27 price.
Bear case: the Economic Profit group reads lowest at $1.57, and 8 of the 21 models stay below the price. Evidence for this calculation is medium.
Scenario range: $3.18 (bear) to $6.18 (bull), the price of $4.27 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Ironwood Pharmaceuticals Inc reported revenue of $296M in FY2025 versus $414M in FY2021, a compound −8.0%/yr. Reported net income was $24.0M in FY2025, compounding −53.8%/yr from FY2021.
Key figures
Market cap $759M · P/E ratio 6.9 · P/S ratio 0.56 · EPS (TTM) $0.6200 · Net margin 8.1% · Return on equity −575% · Return on assets (EBIT) −20.2% · Operating margin 68.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 21% below its 52-week high and 236% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −1%, IRWD screens cheaper than that median.
Fair Value models
Bear $3.18Fair Value $4.23Bull $6.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.4535 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−14.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 27%
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −7.1% a year for the price and +9.8% for the forecasts.
Compare Ironwood Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−1% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets33% · Top 25%
Net margin (TTM)28% · Top 25%
Operating margin (TTM)68% · Top 25%
Growth and dividend
Revenue growth159% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)6.9× · Cheapest 25%
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)2.10× · Pricier than median
P/FCF6.0× · Pricier than median
EV/EBITDA4.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)32· sector 14
FUTURE (revenue growth)100· sector 21
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ironwood Pharmaceuticals Inc (IRWD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $4.23 versus a price of $4.27, about −1% upside (fairly valued).
What is the fair value of IRWD?
Our model-based fair value for Ironwood Pharmaceuticals Inc is $4.23 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.27.
What is the quality score of IRWD?
Ironwood Pharmaceuticals Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ironwood Pharmaceuticals Inc (IRWD)?
Our model-based price target is the fair value of $4.23 (as of Sep 23, 2026) from 21 valuation models. Cautious scenario $3.18, optimistic scenario $6.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Ironwood Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $4.23, about −1% upside versus a price of $4.27 (fairly valued). Cautious scenario $3.18, optimistic scenario $6.18. The calculation is refreshed regularly with new filings.
What is the revenue of Ironwood Pharmaceuticals Inc (IRWD)?
Ironwood Pharmaceuticals Inc reported trailing-twelve-month revenue of about $362M (latest available figure, as of Sep 23, 2026).
What growth is priced into Ironwood Pharmaceuticals Inc (IRWD)?
For today's price to be fair in a discounted-cash-flow model, Ironwood Pharmaceuticals Inc would have to grow free cash flow by -4.9 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of IRWD use?
Our models discount Ironwood Pharmaceuticals Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.24, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ironwood Pharmaceuticals Inc that is -4.9 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Ironwood Pharmaceuticals Inc (IRWD) delivered so far?
Over the past 5 years revenue at Ironwood Pharmaceuticals Inc grew -5.3 % a year. The price currently implies -4.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ironwood Pharmaceuticals Inc (IRWD) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Ironwood Pharmaceuticals Inc (-4.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ironwood Pharmaceuticals Inc (IRWD)?
The free-cash-flow yield on the price is 16.73 %: that much free cash flow Ironwood Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ironwood Pharmaceuticals Inc (IRWD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ironwood Pharmaceuticals Inc it is $4.23 per share (as of Sep 23, 2026), against a price of $4.27. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Ironwood Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IRWD trades above its calculated fair value: price $4.27, fair value $4.23, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRWD?
No. The price is what the market pays today ($4.27); the fair value is what the company's own numbers justify ($4.23). For Ironwood Pharmaceuticals Inc the two are $0.0390 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ironwood Pharmaceuticals Inc worth?
The market values Ironwood Pharmaceuticals Inc at about $759M (market capitalisation, as of Sep 23, 2026). Per share that is $4.27; our models calculate a fair value of $4.23 per share.
What do the bullish and bearish scenarios say about IRWD?
Our models span a range for Ironwood Pharmaceuticals Inc: cautious scenario $3.18, base $4.23, optimistic $6.18 per share (as of Sep 23, 2026, price $4.27). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IRWD?
Ironwood Pharmaceuticals Inc trades at a price-to-earnings ratio of 6.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.23 is built from several models across several years. Other multiples: P/S 2.1, EV/EBITDA 4.6.
How solid is the balance sheet of Ironwood Pharmaceuticals Inc (IRWD)?
Balance-sheet figures for Ironwood Pharmaceuticals Inc (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is IRWD from its 52-week high?
Ironwood Pharmaceuticals Inc trades at $4.27, about 21% below its 52-week high of $5.39 and 236% above the low of $1.27 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $4.23 is for.
Which stocks are comparable to Ironwood Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ironwood Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $4.27, calculated fair value $4.23 (−1%), Quality Score 70/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IRWD calculated?
We run Ironwood Pharmaceuticals Inc through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.23, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Ironwood Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ironwood Pharmaceuticals Inc (IRWD)?
The closing price on Sep 23, 2026 was $4.27. Our model-based fair value is $4.23, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ironwood Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($3.18 to $6.18) leaves room in how you read the outcome.
Key figures of Ironwood Pharmaceuticals Inc
How large is the market capitalisation of Ironwood Pharmaceuticals Inc (IRWD)?
The market capitalisation of Ironwood Pharmaceuticals Inc is $759M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ironwood Pharmaceuticals Inc (IRWD)?
The price-to-sales ratio of Ironwood Pharmaceuticals Inc is 0.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ironwood Pharmaceuticals Inc (IRWD)?
Earnings per share at Ironwood Pharmaceuticals Inc are $0.6200 (price ÷ EPS = P/E 6.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ironwood Pharmaceuticals Inc (IRWD)?
The net margin of Ironwood Pharmaceuticals Inc is 8.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ironwood Pharmaceuticals Inc (IRWD)?
The return on equity (ROE) of Ironwood Pharmaceuticals Inc is −575% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ironwood Pharmaceuticals Inc (IRWD)?
On an EBIT basis the return on assets of Ironwood Pharmaceuticals Inc is −20.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ironwood Pharmaceuticals Inc (IRWD)?
The operating margin of Ironwood Pharmaceuticals Inc is 68.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ironwood Pharmaceuticals Inc (IRWD)?
Revenue at Ironwood Pharmaceuticals Inc is growing +159% versus a year earlier (3y avg −10.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ironwood Pharmaceuticals Inc (IRWD)?
Earnings per share at Ironwood Pharmaceuticals Inc are growing +10.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Ironwood Pharmaceuticals Inc (IRWD) carry?
The net debt of Ironwood Pharmaceuticals Inc is $382M (fiscal year 2025, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ironwood Pharmaceuticals Inc in the live analysis
One click puts Ironwood Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026